Costs and effects in therapy for acute coronary syndromes: The case of abciximab in high-risk patients undergoing percutaneous transluminal coronary angioplasty in the EPIC study - 09/09/11
Abstract |
Cost-effectiveness analyses are routinely performed to determine whether the additional cost of a novel therapy is balanced by additional effectiveness. The definitions of costs and effects involve a variety of assumptions, both in general economic terms and with regard to the specific medical setting under consideration. Similarly, differing criteria for acceptability of cost-effectiveness estimates can be used to generate different conclusions regarding cost-effectiveness. The issues and problems inherent in economic evaluation are discussed by an analysis of findings with the platelet glycoprotein IIb/IIIa inhibitor abciximab in the EPIC (Evaluation of 7E3 for the Prevention of Ischemic Complications) study in high-risk patients undergoing percutaneous transluminal coronary angioplasty. (Am Heart J 1998;135:S98-S106.)
Le texte complet de cet article est disponible en PDF.Plan
 | From aErasmus University Rotterdam; bEli Lilly and Company, Indianapolis; cCentocor, Inc., Malvern |
| Reprint requests: Ben A. van Hout, PhD, IMTA/Room L4-070, Erasmus University Rotterdam, Postbus 1738, 3000 DR, Rotterdam, The Netherlands. |
 | 4/0/88302 |
Vol 135 - N° 4
P. s98-s106 - avril 1998 Retour au numéro
Article précédent
- Abciximab therapy in percutaneous intervention: Economic issues in the United States
- Anil K. Goklaney, Joshua D. Murphy, William B. Hillegass
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?